Pear Therapeutics, Inc. Warrant
PEARW
PEARW was delisted on the 18th of April, 2023.
33 hedge funds and large institutions have $709K invested in Pear Therapeutics, Inc. Warrant in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
0% more funds holding
Funds holding: 33 → 33 (0)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
80% less capital invested
Capital invested by funds: $3.57M → $709K (-$2.86M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Difesa Capital Management
New York
|
+$24.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.66K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.15K |
| 4 |
LC
Littlejohn & Co
Greenwich,
Connecticut
|
+$802 |
| 5 |
BCM
BCK Capital Management
Stamford,
Connecticut
|
+$32 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$3.98K |
| 2 |
AGC
Angelo Gordon & Co
New York
|
-$3.21K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$857 |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$424 |
| 5 |
FTUS
Flow Traders U.S.
New York
|
-$375 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
26
BCK Capital Management
Stamford,
Connecticut
| $250 | +$32 | +330 | +3% |
|
27
Walleye Trading
New York
| $203 | – | – | – |
|
|
LC
28
Littlejohn & Co
Greenwich,
Connecticut
| $158 | +$802 | +8,332 | New |
|
|
WTA
29
Washington Trust Advisors
Wellesley,
Massachusetts
| $20 | – | – | – |
|
30
Morgan Stanley
New York
| $14 | – | – | – |
|
|
AGC
31
Angelo Gordon & Co
New York
| – | -$3.21K | -33,332 | Closed |
|
|
FTUS
32
Flow Traders U.S.
New York
| – | -$375 | -3,895 | -28% |
|
33
UBS Group
Zurich,
Switzerland
| – | -$375 | -2,500 | Closed |
|
PEARW Hedge Fund Activity: Q1 2023 in Review
33 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Warrant (PEARW) for Q1 2023, worth a combined $709K — down 80% from $3.57M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PEARW positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Difesa Capital Management, adding an estimated $24.1K. The largest seller was Walleye Capital, cutting an estimated $3.98K.
- 33 institutional investors held Pear Therapeutics, Inc. Warrant (PEARW) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $709K of Pear Therapeutics, Inc. Warrant stock for Q1 2023, down 80% quarter-over-quarter.
- 4 funds opened new Pear Therapeutics, Inc. Warrant positions in Q1 2023 and 2 closed out, a net change of +2 holders.
- The largest Pear Therapeutics, Inc. Warrant buyer in Q1 2023 was Difesa Capital Management, an estimated $24.1K added.
- The largest Pear Therapeutics, Inc. Warrant seller in Q1 2023 was Walleye Capital, an estimated $3.98K sold.
Based on aggregated 13F filings for Q1 2023.